Roquefort Therapeutics moves into ‘cutting edge cancer treatments’ with Oncogeni buy

Roquefort Therapeutics PLC (LON:ROQ) joined Proactive London to discuss its acquisition of Oncogeni and £1mln of new funding.

Newly appointed CEO, Ajan Reginald, told Chris Rhodes of the plans for the money and the work now underway with Oncogeni.

Working on cutting-edge treatments for hard-to-treat cancers, Reginald said the new acquisition and its expertise in drugs and rolling out treatments would substantially enhance its existing portfolio.

#Roquefort Therapeutics #Oncomgeni #AIM #Cancer

You might like

© 2022 Stockmark.it The Latest StockMarket News and Interviews